21-762 N/A
A Phase 0 clinical trial to evaluate drug concentrations and pharmacodynamic parameters of niraparib in tumor tissue of patients with surgically accessible recurrent IDH 1/2 gliomas
A Phase 0 clinical trial to evaluate drug concentrations and pharmacodynamic parameters of niraparib in tumor tissue of patients with surgically accessible recurrent IDH 1/2 gliomas
A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas
A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination with Radiation Therapy in Patients with Glioblastoma Multiforme and Brain Metastases from Solid Tumors
A Surgical “Window-of-Opportunity” and Phase II Trial of Pembrolizumab, Olaparib and Temozolomide in Recurrent Glioblastoma
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
A071401: Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Mutations
Glioblastoma Adaptive, Global, Innovative Learning Environment (GBM AGILE)
INCIPIENT: INtraventricular CARv3-TEAM-E T Cells for PatIENTs with GBM
Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)